CLOVER BIO-B

Clover Biopharmaceuticals rallied in the afternoon session, climbing from a session low of 1.66 HKD to an intraday high of 1.79 HKD, before closing at 1.77 HKD, up 4.1% from the previous close of 1.70 HKD, with an intraday range of 8.2%. The move was catalyzed by news of a cap-limited settlement with Gavi to terminate arbitration, alleviating a US$224 million exposure. Year-to-date, the stock is down 25.3%, trading 44.7% below its 52-week high of 3.2 HKD. While the current price sits above the 20-day moving average (1.66 HKD), it remains below the 60-day moving average (2.37 HKD). Q4 revenue plunged 99.5% YoY to HK$140 thousand, though net loss narrowed 86.6%, with EPS improving to -0.046 HKD. Net profit margin, however, remains deeply negative, underscoring the distance to a sustainable recovery.